We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Three Supplementary Genes Linked to Breast Cancer

By LabMedica International staff writers
Posted on 16 May 2011
A newly discovered association has been found between three genes and the most common form of breast cancer. More...


The genes were found directly next to the estrogen receptor gene, the main driver of hormonal breast cancer. The estrogen receptor has been intensively studied by scientists for decades and is located in one of the intensively studied areas of the genome.

Scientists at The Institute of Cancer Research, (ICR; London, UK), studied 104 patients with hormonal, also known as estrogen receptor (ER) positive, breast cancer. They wanted to find the genes that were most closely linked to the estrogen receptor. The three genes identified were: chromosome 6 open reading frame 96 (C6ORF96), C6ORF97, and C6ORF211. All three were found to be linked to the estrogen receptor, but working separately from it. As a result, their activity is unlikely to be affected by current treatments, such as tamoxifen, which target the estrogen receptor. This could mean that they are potential targets for new drug treatments.

The human gene C6ORF211 was shown to drive the growth of tumors and the team sees this as the most likely target for new treatments. The gene C6ORF97 was shown to be an indicator of a tumor not relapsing, and also a good predictor of response to tamoxifen. Less is known about the gene C6ORF96, but it is being investigated by the team.

Mitchell Dowsett, PhD, professor of biochemical endocrinology at the ICR, said, "This investigation is exciting because it shows that while the estrogen receptor is the main driver of hormonal breast cancer, there are others next door to it that also appear to influence breast cancer behavior. We now need to better understand how they work together and how we can utilize them to save lives of women with breast cancer." In Britain, nearly 48,000 women and around 300 men are diagnosed every year with breast cancer; the most diagnosed commonly cancer in the UK.

Related Links:

The Institute of Cancer Research




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.